GeneReach Biotechnology Corp. (TPEX:4171)

-32.75% (1Y)

Market Cap	1.31B
Revenue (ttm)	213.05M
Net Income (ttm)	-108.81M
Shares Out	57.46M
EPS (ttm)	-1.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,651
Average Volume	633,157
Open	23.00
Previous Close	22.75
Day's Range	22.85 - 23.30
52-Week Range	15.40 - 38.15
Beta	0.16
RSI	47.81
Earnings Date	Aug 11, 2025

About GeneReach Biotechnology

GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers automatic nucleic acid extraction systems, prep homogenization system, and mini centrifuge equipment; and reagents and consumables, comprising human IVD assays, iiPCR specific reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and research reagents and consumables. It also provides polymerase chain reaction training programs (PC...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4171

Financial Performance

In 2024, GeneReach Biotechnology's revenue was 206.49 million, a decrease of -8.41% compared to the previous year's 225.46 million. Losses were -118.73 million, -28.59% less than in 2023.